QuidelOrtho Corporation (NASDAQ: QDEL) has announced the appointment of John R. Chiminski and R. Scott Huennekens to its board of directors, effective December 6, 2024. These appointments come as the company continues to strengthen its leadership team and board, aiming to capitalize on their expertise and experience for further growth and transformation.
John R. Chiminski, a former CEO and board chair, brings a diversified medical diagnostics and pharmaceutical background to the board. He served as the CEO of Catalent (NYSE: CTLT) from 2009 to 2022 and played a pivotal role in establishing Catalent as a standalone public company after its carve-out from Cardinal Health. Prior to that, he spent over 20 years with GE Healthcare, ultimately serving as the President and CEO of GE Medical Diagnostics, a global business with $1.9 billion in sales.
R. Scott Huennekens, another seasoned industry executive, has been involved in over 20 startups and public companies. He served as the Chair, President, and CEO of Verb Surgical, an independent surgical technology start-up jointly formed by Google and Johnson & Johnson, from 2015 to 2019. Huennekens has also held leadership positions at notable companies such as Volcano Corporation and Digirad Corporation.
The new appointments come following the resignation of James R. Prutow and Robert R. Schmidt from the board, effective November 21, 2024. With these changes, the board will now comprise 11 directors, 10 of whom are independent.
QuidelOrtho remains committed to advancing diagnostics and is focused on executing its transformational strategy, delivering enhanced financial results, and introducing innovative technologies to improve diagnostic testing and patient outcomes. Following these announcements, the company's shares moved -3.2%, and are now trading at a price of $39.23. If you want to know more, read the company's complete 8-K report here.
